12,380 real negative results, null findings, and replication failures in Medicine. Search the index →
WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record compiled from open scholarly databases; the abstract is shown in full only where the paper is openly licensed, otherwise a short excerpt under fair use. Classifications are automated and approximate.
Pravisano F, Costa J, Marchi L et al. · 2026 · Cancers
The role of adjuvant therapy in stage III melanoma is well established in clinical practice. Because stage IIB-IIC melanoma carries a risk of recurrence and melanoma-specific mortality comparable to that of stage III disease, adjuvant…
View details →Agnihotri G, Lio PA · 2020 · Clinical drug investigation
Multiple pathways contribute to the pathogenesis of atopic dermatitis (AD), and various targeted topical, biologic, and oral systemic agents have subsequently been developed. This review examines the mechanism of action and study designs…
View details →Geurts VCM, Voorwerk L, Balduzzi S et al. · 2023 · Breast (Edinburgh, Scotland)
The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die of this disease. Despite, relatively high levels of stromal tumor infiltrating lymphocytes…
View details →Da Cruz RS, Teague HL, Ramos-Benitez MJ et al. · 2026 · Critical care explorations
Objectives Understanding the mechanistic impact of fostamatinib, a spleen tyrosine kinase inhibitor, in severe COVID-19 using biomarkers associated with disease severity is crucial for the development of host-directed therapeutics. We…
View details →Ishikawa M, Shibata T, Iwata T et al. · 2021 · Gynecologic oncology
Objective To assess the efficacy and safety of dose-dense weekly paclitaxel plus carboplatin (ddTC) with or without bevacizumab compared to conventional, tri-weekly paclitaxel plus carboplatin (cTC) with or without bevacizumab, in…
View details →Juárez-García M, Plasencia-Rodríguez C, Benavent D et al. · 2026 · Therapeutic advances in musculoskeletal disease
Background Axial spondyloarthritis (axSpA) is an inflammatory disease in which, despite expanding therapeutic options, a substantial proportion of patients do not achieve the desired treatment target, highlighting the emerging concept of…
View details →Rimel BJ, Enserro D, Bender DP et al. · 2024 · Cancer
Purpose This paper reports the efficacy of the poly (ADP-ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer.…
View details →Marder G, Quach T, Chadha P et al. · 2024 · Rheumatology (Oxford, England)
Objective To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). Methods We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV…
View details →White RA, Mezzano-Robinson V, Shi Q et al. · 2025 · The oncologist
Background The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic adenocarcinoma (PDAC) by inhibiting cancer stem cells and suppressing inflammatory cytokine…
View details →Zhang CD, Zhou JS, He LY et al. · 2025 · Frontiers in cardiovascular medicine
Objective The aim of this study was to investigate the quantitative flow ratio (QFR) outcomes in the left circumflex artery (LCX) following the placement of a crossover stent from the left main coronary artery (LM) to the left anterior…
View details →Raychaudhuri R, Cheng HH, Gulati R et al. · 2026 · European urology oncology
Background and objective Our aim was to determine whether induction chemotherapy followed by PARP inhibitor (PARPi) maintenance improves outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…
View details →Choi SW, Jung HA, Cho HJ et al. · 2023 · Cancer medicine
Background We evaluated the therapeutic efficacy of GC1118, a novel anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in recurrent glioblastoma (GBM) patients with EGFR amplification. Methods This study was a multicenter,…
View details →Voglová B, Hladíková Z, Nemétová L et al. · 2020 · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Early worsening of diabetic retinopathy due to sudden glucose normalization is a feared complication of pancreas transplantation; however, its rate or severity has not been studied prospectively. We followed up 43 pancreas and kidney…
View details →Breen WG, Dixon JG, Anderson SK et al. · 2025 · Neuro-oncology
Background Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. Methods North Central Cancer Treatment Group N0877 is a phase 1 dose…
View details →Jacobsen LM, Schatz D · 2025 · Hormone research in paediatrics
Background Type 1 diabetes (T1D) is more than an insulin-deficiency disease - it is an autoimmune disease, and the field is moving toward adopting disease-modifying immunotherapy as part of clinical care during T1D development. Summary…
View details →Çalışkan B · 2025 · International ophthalmology
Purpose To evaluate serum lipid profiles with triglyceride-Glucose (TyG) and TG/HDL-c indices in patients with exudative type age-related macular degeneration. Methods A total of 71 participants were included in the study: 35 with…
View details →Davidson TM, Lebreton CL, Hendricksen AEW et al. · 2023 · Gynecologic oncology
Background IGF signaling has been implicated in the pathogenesis and progression of ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a fully human monoclonal antibody against IGF1R that blocks binding of…
View details →O'Hara MH, Jegede O, Dickson MA et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests that inhibition of CDK4/6 is a plausible treatment strategy in these tumors. Subprotocol Z1C of…
View details →Taccetti G, Terlizzi V, Campana S et al. · 2024 · European journal of pediatrics
Bacterial infections of the lower airways are the main cause of mortality and morbidity in cystic fibrosis. The most frequently isolated pathogens are S. aureus and P. aeruginosa; bacterial co-infections are frequently observed. The aim of…
View details →Schott CA, Mohning MP, Cooley JC · 2025 · Seminars in respiratory and critical care medicine
Idiopathic pulmonary fibrosis (IPF) is a rare but devastating diagnosis for patients with only two approved drug therapies. Extensive preclinical studies have identified and characterized novel pathways driving IPF pathogenesis, and…
View details →Mosca M, Arnaud L, Askanase A et al. · 2025 · Lupus science & medicine
Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib 3 mg two times per day dose. Changes in…
View details →Bateman RJ, Li Y, McDade EM et al. · 2025 · The Lancet. Neurology
Background Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The…
View details →Hamamoto H, Suzuki Y, Takano Y et al. · 2022 · BMC surgery
Background This retrospective study aimed to compare long-term oncological outcomes between laparoscopic-assisted colectomy (LAC) with extracorporeal anastomosis (EA) and totally laparoscopic colectomy (TLC) with intracorporeal anastomosis…
View details →Borghaei H, O'Byrne KJ, Paz-Ares L et al. · 2023 · ESMO open
Background In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% versus…
View details →Cacko A, Kozyra-Pydyś E, Gawałko M et al. · 2021 · Cardiology journal
Background Among patients with an implanted cardiac implantable electronic device (CIED), ipsilateral upper extremity vein stenosis or occlusion (VSO) is observed more frequently than in the general population. However, there are no data…
View details →Choueiri TK, Albiges L, Barthélémy P et al. · 2024 · Lancet (London, England)
Background Immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor tyrosine kinase inhibitors are cornerstones of first-line treatment for advanced renal cell carcinoma; however, optimal treatment sequencing…
View details →Konno Y, Mayama M, Takehara K et al. · 2025 · Journal of gynecologic oncology
Objective This study aimed to assess the prognostic significance of para-aortic lymphadenectomy (PALX) and para-aortic lymph node metastasis in endometrial cancer (EC) patients at risk of post-operative recurrence. Methods Japanese…
View details →Pettengell R, Długosz-Danecka M, Andorsky D et al. · 2020 · British journal of haematology
PIX306 was a phase 3, randomised, single-blind, multicentre trial conducted in adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not…
View details →Tolaney SM, Sahebjam S, Le Rhun E et al. · 2020 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose The primary objective was to evaluate intracranial objective response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to hormone receptor-positive (HR + ) metastatic breast…
View details →Rascol O, Tönges L, deVries T et al. · 2022 · Parkinsonism & related disorders
Background Immediate-release (IR) amantadine has been used for treatment of levodopa induced dyskinesia (LID). The immediate-release/extended-release (IR/ER) amantadine formulation OS320 (OSMOLEX ER®) contains an IR outer layer and ER core…
View details →